CRNX CRINETICS PHARMACEUTICALS INC Operational Disruptions 8-K Filing 2024 - Positive Findings from Development Program Crinetics Pharmaceuticals announced positive initial findings from the development program of its second clinical product candidate, atumelnant, and findings from its clinical development program evaluating paltusotine.Get access to all SEC 8-K filings of the CRINETICS PHARMACEUTICALS INC